Bio-Techne Broadens 3D Stem Cell and Organoid Culture Offerings with a Fully Defined, Synthetic Matrix Alternative Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced the launch of Cultrex™ Synthetic Hydrogel, a fully defined…
Novo Nordisk A/S: CagriSema Shows Superior HbA1c Reduction of 1.91% and 14.2% Weight Loss in Adults with Type 2 Diabetes in REIMAGINE 2 Trial Novo Nordisk today announced headline results from REIMAGINE 2, a phase 3 trial from the global…
AstraZeneca Expands Weight Management Portfolio via Collaboration with CSPC Pharmaceuticals AstraZeneca strengthens its weight management portfolio through a new strategic collaboration agreement with CSPC Pharmaceuticals to advance the development of multiple next-generation therapies for obesity and type 2 diabetes across…
Glaukos Announces FDA Approval for Re-Administration of iDose® TR Glaukos Corporation, an ophthalmic pharmaceutical and medical technology focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that the U.S. Food and Drug Administration…
BioNTech Appoints Kylie Jimenez as Chief People Officer to Management Board BioNTech SE announced today that the Supervisory Board has appointed Kylie Jimenez to the Management Board as Chief People Officer (“CPO”) effective March 1, 2026. The appointment is in line…
This is the place for emergency medicine’ features real people working in emergency departments in Coventry and Manchester. Commissioned by the Royal College of Emergency Medicine (RCEM), the film is a snapshot of life in A&E – ‘where excellence is…
Will Forte Partners with Teva to Launch “Honestly HD”—A Candid Conversation About Huntington’s Disease Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced a partnership with actor, comedian and advocate, Will Forte, to…
Neurocrine Biosciences Launches Phase 2 Trial of NBI-1065890 for Tardive Dyskinesia in Adults Neurocrine Biosciences, Inc. today announced the initiation of its Phase 2 clinical study of investigational compound NBI-1065890 in adults with tardive dyskinesia (TD). NBI-1065890 is a next-generation,…
WuXi Biologics and HanchorBio Forge Strategic Partnership to Advance Next-Gen Bi- and Multi-Functional Fusion Proteins WuXi Biologics, a global leading Contract Research, Development and Manufacturing Organization (CRDMO), and HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies…
Trelegy Ellipta Gains Approval in China for Adults with Uncontrolled Asthma GSK plc today announced that China’s National Medical Products Administration (NMPA) has approved a new indication for Trelegy Ellipta (fluticasone furoate / umeclidinium / vilanterol ‘FF/UMEC/VI’) for the treatment of patients…
Lilly’s Sacituzumab Govitecan Receives U.S. FDA Breakthrough Therapy Designation for Platinum-Resistant Ovarian Cancer Eli Lilly and Company today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to sofetabart mipitecan (LY4170156) for the treatment of adult patients…
Moderna and Merck Report Five-Year Data Showing Sustained Improvement in Recurrence-Free Survival with Intismeran Autogene Plus KEYTRUDA® in High-Risk Stage III/IV Melanoma Patients After Complete Resection Moderna, Inc. and Merck (NYSE: MRK), known as MSD outside of the United States and…
